Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Progenics Pharmaceuticals Inc (NASDAQ:PGNX)

6.27
Delayed Data
As of Jan 19
 0.00 / 0.00%
Today’s Change
4.60
Today|||52-Week Range
11.72
+5.38%
Year-to-Date
Reversal Offers Chance in 2 Small Biotechs
Jan 17 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close6.27
Today’s open6.10
Day’s range6.08 - 6.30
Volume1,303,566
Average volume (3 months)1,065,927
Market cap$440.6M
Data as of 4:00pm ET, 01/19/2018

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)-704.00%
Earnings growth (next 5 years)+2.00%
Revenue growth (last year)+700.24%
P/E ratioNM
Price/Sales8.73
Price/Book4.20

Competitors

 Today’s
change
Today’s
% change
ABEOAbeona Therapeutics ...0.000.00%
ASMBAssembly Biosciences...0.000.00%
KPTIKaryopharm Therapeut...0.000.00%
CMTAClementia Pharmaceut...0.000.00%
Data as of 4:00pm ET, 01/19/2018

Financials

Next reporting dateMarch 15, 2018
EPS forecast (this quarter)-$0.23
Annual revenue (last year)$69.4M
Annual profit (last year)$10.8M
Net profit margin15.56%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Mark Robert Baker
CFO, Principal Accounting Officer &
Senior VP
Patrick Fabbio
Corporate headquarters
New York, New York

Forecasts